• 
  Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
• 
  P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩
• 
  Charlotte Demoor-Goldschmidt, Stéphane Supiot, Marc-André Mahé, Odile Oberlin, Rodrigue Allodji, et al.. Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy. British Journal of Radiology, 2018, 91 (1086), pp.20170824. ⟨10.1259/bjr.20170824⟩. ⟨inserm-04439735⟩
• 
  Imène Mansouri, Rodrigue S Allodji, Catherine Hill, Chiraz El‐fayech, François Pein, et al.. The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer. European Journal of Heart Failure, 2018, 21 (4), pp.509 - 518. ⟨10.1002/ejhf.1376⟩. ⟨inserm-04439245⟩
• 
  Maria John, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, et al.. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors. Advances in Anatomic Pathology, 2017, 24 (6), pp.311 - 335. ⟨10.1097/PAP.0000000000000161⟩. ⟨hal-01675236⟩
• 
  Maria John, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, et al.. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors. Advances in Anatomic Pathology, 2017, 24 (5), pp.235 - 251. ⟨10.1097/PAP.0000000000000162⟩. ⟨hal-01675241⟩
• 
  Manon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, et al.. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. Journal for Immunotherapy of Cancer, 2023, Journal for ImmunoTherapy of Cancer, 11 (11), pp.e006885. ⟨10.1136/jitc-2023-006885⟩. ⟨hal-04341909⟩
• 
  Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, et al.. Impact of body mass index on overall survival in patients with metastatic breast cancer. The Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩. ⟨hal-03345238⟩
• 
  Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
• 
  Alexandre Bertucci, F. Bertucci, Christophe Zemmour, Florence Lerebours, Jean-Yves Pierga, et al.. PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. Frontiers in Oncology, 2020, 10, ⟨10.3389/fonc.2020.575978⟩. ⟨hal-03623650⟩
• 
  C. Robert, A. Munoz, D. Moreau, J. Mazurier, G. Sidorski, et al.. Clinical implementation of deep-learning based auto-contouring tools–Experience of three French radiotherapy centers. Cancer/Radiothérapie, 2021, 25 (6-7), pp.607-616. ⟨10.1016/j.canrad.2021.06.023⟩. ⟨hal-03797764⟩
• 
  Clémence Basse, Antoine Italiano, Nicolas Penel, Olivier Mir, Claire Chemin, et al.. Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years. International Journal of Cancer, 2019, 145 (8), pp.2135-2143. ⟨10.1002/ijc.32307⟩. ⟨hal-02504786⟩
• 
  Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, et al.. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature Medicine, 2023, 29 (8), pp.2110 - 2120. ⟨10.1038/s41591-023-02478-2⟩. ⟨hal-04187928⟩
• 
  D. Dano, A. Lardy-Cleaud, A. Monneur, N. Quenel-Tueux, C. Levy, et al.. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open, 2021, 6 (4), pp.100220. ⟨10.1016/j.esmoop.2021.100220⟩. ⟨hal-03426433⟩
• 
  Clémence Romeo, Olivia Le Saux, Margaux Jacobs, Florence Joly, Gwenael Ferron, et al.. Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network. Cancers, 2022, 14 (2), pp.354. ⟨10.3390/cancers14020354⟩. ⟨hal-03622814⟩
• 
  Tina Lamy, Bastien Cabarrou, David Planchard, Xavier Quantin, Sophie Schneider, et al.. Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. Cancers, 2021, 14 (1), pp.92. ⟨10.3390/cancers14010092⟩. ⟨hal-04142072⟩
• 
  Victoria Corvest, Perrine Marec-Bérard, Cyril Lervat, Hélène D. Pacquement, Maud Toulmonde, et al.. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France. International Journal of Cancer, 2023, 152 (8), pp.1659-1667. ⟨10.1002/ijc.34326⟩. ⟨hal-04122360⟩
• 
  Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, 2022, 16 (10), pp.2057-2070. ⟨10.1002/1878-0261.13188⟩. ⟨hal-03583253⟩
• 
  Anne-Sophie Sertier, Anthony Ferrari, Roxane Pommier, Isabelle Treilleux, Sandrine Boyault, et al.. Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas. Cancer Research Communications, 2023, 3 (5), pp.830-841. ⟨10.1158/2767-9764.CRC-22-0520⟩. ⟨hal-04104571⟩
• 
  Francois-Xavier Danlos, Matthieu Texier, Bastien Job, Severine Mouraud, Lydie Cassard, et al.. Genomic Instability and Pro-Tumoral Inflammation are associated with Primary Resistance to Anti-PD1 + Anti-Angiogenesis in Malignant Pleural Mesothelioma. Cancer Discovery, 2023, pp.OF1-OF22. ⟨10.1158/2159-8290.CD-22-0886⟩. ⟨hal-03972355⟩

123

178